Closure of Trading Window
Neuland Laboratories Ltd has informed BSE that a meeting of Board of Directors of the Company will be held on May 08, 2015, inter alia, to consider and take on record the Audited financial results of the Company for the year ended March 31, 2015.Further, as per the provisions of the Code of Conduct for Prevention of Insider Trading of the Company, the Trading Window for transactions in shares of the Company is closed from April 22, 2015 to... Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Neuland Laboratories Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992 Shareholding Pattern For March 31, 2015
Neuland Laboratories Ltd has informed BSE about the Shareholding Pattern as on March 31, 2015. Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Neuland Laboratories Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992 Disclosure under clause 53 of the listing agreement
Neuland Laboratories Ltd has informed BSE regarding Disclosure under clause 53 of the listing agreement. Financial Results & Limited Review for Dec 31, 2014 (Standalone)
Neuland Laboratories Ltd has informed BSE about the Standalone Financial Results & a copy of the Limited Review Report for the period ended December 31, 2014. Shareholding Pattern For December 31, 2014
Neuland Laboratories Ltd has informed BSE about the Shareholding Pattern as on December 31, 2014. Closure of Trading Window
Neuland Laboratories Ltd has informed BSE that a meeting of Board of Directors of the Company will be held on January 30, 2015, inter alia, to consider and take on record the unaudited financial results of the Company for the quarter ended December 31, 2014.Further, as per the provisions of the Code of Conduct for Prevention of Insider Trading of the Company, the Trading Window for transactions in shares of the Company is closed from January... Allotment of Equity Shares on Rights basis to non-resident shareholders
Neuland Laboratories Ltd has informed BSE that pursuant to receipt of approval of Foreign Investment Promotion Board ("FIPB"), the Board of Directors of the Company had, on December 17, 2014, allotted 2,804 fully paid up equity shares of a face value of Rs. 10/- each, out of the Rights Issue of 12,25,276 Equity Shares. The allotment of these 2,804 equity shares was kept in abeyance, pending FIPB approval.... Change in Directorate
Neuland Laboratories Ltd has informed BSE that Export Import Bank of India ("EXIM Bank") has withdrawn the nomination of Mr. Nadeem Panjetan as a Director on the Board of the Company, w.e.f. December 08, 2014.Consequently, Mr. Nadeem Panjetan ceases to be a Director of the Company.